Actively Recruiting
Blood-based Biomarkers for Early Alzheimer's Disease Screening
Led by Peking University First Hospital · Updated on 2024-06-27
180
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are investigating blood biomarkers to improve early screening for Alzheimer's disease (AD). This observational study focuses on patients with AD, mild cognitive impairment (MCI) due to AD, and cognitively normal individuals. The goal is to identify key blood biomarkers suitable for early detection and to build a comprehensive model combining biomarkers and clinical information. The study is sponsored by Peking University First Hospital. Participants will have blood samples taken to test for specific biomarkers including Aβ40, Aβ42, P-Tau181, P-Tau217, GFAP, and NfL. These tests aim to evaluate their diagnostic accuracy for Alzheimer's and MCI. The study will observe individuals at different stages of cognitive health to understand how these biomarkers perform across groups. During the two-year study period, participants will undergo cognitive assessments and blood draws as part of the evaluation. Researchers will monitor the accuracy of these biomarkers in diagnosing AD and MCI. The study also aims to develop a model that combines blood biomarker results with clinical information to aid early identification. Participation involves regular assessments and cooperation with blood sampling and cognitive testing.
CONDITIONS
Brief Title
Blood Biomarkers for Screening of Alzheimer's Disease
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 65 50 years
- Diagnosis of Alzheimer's disease according to 2011 NIA-AA criteria, mild cognitive impairment by 2004 Peterson criteria, or cognitively normal status
- Signed informed consent form
You will not qualify if you...
- Presence of other disorders causing cognitive impairment
- Unable to cooperate with cognitive assessments
- Refusal to have blood drawn for testing
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 2 years
Participants undergo blood biomarker testing to evaluate markers associated with Alzheimer's disease.
Periodic blood draws over 2 years
Duration - Up to 2 years
Participants are monitored to assess the diagnostic accuracy of blood biomarkers combined with clinical information.
Follow-up assessments during the 2-year period
Trial Site Locations
Total: 1 location
1
Peking University First Hospital
Beijing, Beijing Municipality, China, 100034
Actively Recruiting
Research Team
C
Chen Zhang
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here